Statistics
Publications
45
Citations
12.8K
H-Index
36
Active since
2002
Mark Ayers is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and molecular oncology.
Publications per year
2002–2023
45
45
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers, Jared Lunceford, Michael Nebozhyn et al. · Journal of Clinical Investigation · 2017 · 3.9K citations · Full text
Medicine, Immunology, Oncology +17
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Răzvan Cristescu, Robin Mogg, Mark Ayers et al. · Science · 2018 · 2.3K citations
Medicine, Immunology, Oncology +17
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Roman Rouzier, Charles M. Perou, W. Fraser Symmans et al. · Clinical Cancer Research · 2005 · 1.9K citations · Full text
Medicine, Cancer Biology, Oncology +17
Patrick A. Ott, Yung‐Jue Bang, Sarina A. Piha‐Paul et al. · Journal of Clinical Oncology · 2018 · 992 citations
Medicine, Oncology, Pharmacotherapy +17
Mark Ayers, W. Fraser Symmans, James Stec et al. · Journal of Clinical Oncology · 2004 · 569 citations
Medicine, Cancer Biology, Oncology +17
1–5 of 45